Published Technical Disclosure Archive

Personalized Neuro-Adaptive Treatment System for ADHD

Publication ID: 24-11857592_0005_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Personalized Neuro-Adaptive Treatment System for ADHD,” Published Technical Disclosure No. 24-11857592_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857592_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,592.

Summary of the Inventive Concept

A wearable, AI-driven system for treating attention-deficit hyperactivity disorder (ADHD) by adapting to individual brain activity, genomic data, and behavioral patterns, providing a personalized and optimized treatment plan.

Background and Problem Solved

The original patent disclosed a method for treating ADHD using a Radix Polygalae extract. However, this approach has limitations, such as a one-size-fits-all approach, lack of real-time monitoring, and limited understanding of individual variability. The new inventive concept addresses these limitations by integrating wearable technology, machine learning, and genomic analysis to provide a more effective and personalized treatment.

Detailed Description of the Inventive Concept

The system comprises a wearable device that administers a composition comprising a Radix Polygalae extract, which is configured to monitor and adapt to the subject's brain activity and cognitive performance in real-time. The system utilizes machine learning algorithms to analyze genomic data, brain activity, and behavioral patterns, generating a customized treatment plan. The treatment plan may include a personalized composition comprising a Radix Polygalae extract, which is delivered through a transcranial magnetic stimulation (TMS) device. The system also enables remote monitoring and treatment, allowing for real-time adjustments and optimization.

Novelty and Inventive Step

The new inventive concept introduces a paradigm shift in ADHD treatment by integrating wearable technology, machine learning, and genomic analysis to provide a personalized and optimized treatment plan. This approach is novel and non-obvious compared to the original patent, which relied on a fixed composition and administration method.

Alternative Embodiments and Variations

Alternative embodiments may include using different types of wearable devices, such as implantable devices or mobile applications, or incorporating additional data sources, such as environmental or social factors. Variations may also include using different machine learning algorithms or incorporating additional therapeutic modalities, such as cognitive training or behavioral therapy.

Potential Commercial Applications and Market

The personalized neuro-adaptive treatment system has significant commercial potential in the ADHD treatment market, which is projected to reach $25 billion by 2025. The system's ability to provide personalized and optimized treatment plans, combined with its remote monitoring and treatment capabilities, makes it an attractive solution for patients, clinicians, and payers.

CPC Classifications

SectionClassGroup
A A61 A61K36/69
A A61 A61K9/0053
A A61 A61K9/485
A A61 A61K9/4825
A A61 A61K9/4858
A A61 A61K47/02
A A61 A61K47/12
A A61 A61P25/28
A A61 A61K2236/333

Field of Art

Neurological treatment technologies, specifically pharmaceutical and medical device interventions for attention-deficit hyperactivity disorder (ADHD), involving biotechnology, neuropharmacology, and personalized medical systems

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in neuroscience, biomedical engineering, or pharmaceutical sciences, possessing expertise in neurological treatment design, machine learning applications in medical technologies, and personalized treatment methodologies

Obviousness Rationale

A PHOSITA would recognize that the personalized treatment system represents a predictable technological evolution of the source patent's ADHD treatment approach, leveraging known machine learning and neural monitoring technologies to create a more adaptive therapeutic intervention. The core innovation of using Radix Polygalae extract remains consistent, with the primary advancement being the method of delivery and personalization. These modifications represent standard technological progression in precision medicine and would be considered obvious extensions of the existing treatment methodology.

Obvious Combinations & Variations

Source Patent Element
Radix Polygalae extract composition for ADHD treatment
PTD Variation
Real-time adaptive delivery via wearable neural interface device
Obviousness Reasoning
Combining pharmaceutical compositions with monitoring technologies is a known technique in personalized medicine, representing a predictable application of existing technological capabilities
Source Patent Element
Fixed oral administration method
PTD Variation
Machine learning-driven personalized treatment plan based on genomic and neural data
Obviousness Reasoning
Tailoring pharmaceutical interventions using individual patient data is a standard approach in precision medicine, representing an obvious optimization of treatment protocols
Source Patent Element
Basic ADHD symptom treatment approach
PTD Variation
Transcranial magnetic stimulation integrated with extract delivery
Obviousness Reasoning
Combining pharmaceutical and neurological stimulation techniques is a known approach in neuropharmacological treatment design, representing a finite and predictable solution for enhanced therapeutic intervention
Source Patent Element
Botanical extract for neurological treatment
PTD Variation
Remote monitoring and AI-driven treatment adjustment
Obviousness Reasoning
Implementing digital monitoring and adaptive treatment technologies is a standard evolution in medical treatment methodologies, representing an obvious technological progression
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857592 and the technological context of personalized medical interventions, the claimed variations in the published technical disclosure would be considered obvious to a person having ordinary skill in the art. The combination of known neurological monitoring technologies, machine learning techniques, and the established Radix Polygalae extract treatment methodology represents a predictable and incremental advancement in ADHD treatment technologies, thus rendering potential patent claims obvious and non-patentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,592
TitlePolygala extract for the treatment of attention-deficit hyperactivity disorder
Assignee(s)BioLite Inc.